Clinical Trial

Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study

Recruiting
View on ClinicalTrials.gov →
Summary
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-06-22.
Trial Details
NCT Number NCT05433753
Lead Sponsor National Cancer Center, Japan
Conditions HER2-positive Breast Cancer
Enrollment 60 participants
Start Date 2022-05-24
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-03-25